News >

Ibrutinib Benefit in Waldenstrom Macroglobulinemia Sustained With Latest Data

Danielle Bucco
Published: Wednesday, Mar 01, 2017

Meletios Dimopoulos, MD

Meletios Dimopoulos, MD

Single-agent ibrutinib (Imbruvica) induced a response rate of 90% at a median follow-up of 18.1 months in rituximab-refractory patients with Waldenstrom macroglobulinemia, according to results from an open-label substudy of the ongoing phase III iNNOVATE trial published in The Lancet Oncology.

Common grade 3 adverse events that experienced included neutropenia in 4 patients (13%), hypertension in 3 patients (10%), and anemia, thrombocytopenia, and diarrhea in 2 patients each (6%). There were 10 patients (32%) who experienced serious adverse events, which were most often infections. Overall, 26 patients (84%) continued ibrutinib at the time of the report, while 3 patients discontinued due to progression and 2 discontinued due to adverse events.
Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology. 2017;18(2):241-250. doi:10.1016/s1470-2045(16)30632-5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication